News
Stay Up-To-Date on NEXT Oncology
- All
- NEXT Oncology Blog
- NEXT Oncology News
- Press Releases
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
SAN DIEGO and SHANGHAI, May 5, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, …
Video: Expanded Phase 1 Program to the Dallas Area
In this video hosted by Oncology Tube, Anthony Tolcher, MD, discusses Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area. iFrame is not supported!
SA cancer research company entering Dallas market as it eyes more U.S., European expansion
A cancer research company based in San Antonio is entering the Dallas market as it eyes more U.S. and European expansion… Read the full article at the San Antonio Business …
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced positive monotherapy dose escalation data for its …
MatTek and NEXT Oncology Announce Licensing Agreement
The Boston-based biotech company will use an inventory of patient-derived cancer cells to develop new lab-grown tumor models to accelerate and refine oncology research, and provide more targeted treatments for …
NEXT Oncology Expands Phase I Program to Dallas Area
Expansion makes new break-through anticancer therapies closer to home for more Texans (DALLAS) April 12, 2023 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, …
Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors
The first patient has been dosed with DK210 in a first-in-human, phase 1 clinical trial (NCT05704985) for patients with EGFR-expressing advanced solid tumors.1 “The Diakine™ platform combines the potent anti-cancer function …
Oserdu FDA approval for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …
Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.
Presented at SABCS 2022 by Len-Shu Lu from the National Taiwan University Hospital, Taipei Taiwan. Research remains an essential part of cancer care. In this blog, we will provide information …
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an …